In this article the authors aimed to investigate the consequences of the first COVID-19 lockdown (mid-March - mid-April 2020) on motor and non-motor symptoms (NMS) in a cohort of French people with Parkinson's disease (PwP).

In this article the authors aimed to evaluate the effects of the COVID-19 pandemic on the quality of life (QoL) and perceived disease burden of this group of patients.

In this article the authors aimed to describe the neuropathological findings in SARS-CoV-2 infected patients who died during the COVID-19 pandemic, and define and quantify the presence of virus in selected areas showing pathological signs.

In this study, the authors analyze the characteristics, evaluation, treatment, and in-hospital outcomes of patients presenting with acute ischemic stroke (AIS) pre-COVID-19 and during COVID-19.

In this article the authors report two male patients, aged 45 and 67, who developed a classical form of PD approximately three months after a moderate COVID-19 infection with dyspnea, fever, anosmia and ageusia.

In this review, the authors summarize the current knowledge on epidemiology, clinical manifestation, and pathophysiology of ischemic stroke in patients with COVID-19 to bridge the gap from bench to bedside and clinical practice during the most challenging global health crisis of the last decades.

The purpose of this study was to report real-life safety data of the BNT162b2 COVID-19 vaccine in a cohort of MS patients.

The authors compared clinical features of participants with Tourette Syndrome or Persistent Motor/Vocal Tic Disorder to participants with Rapid Onset Tic-Like Behaviours.

The authors compared post-vaccination CVST to 100 European patients with CVST from before the COVID-19 pandemic derived from the International CVST Consortium.

In this article the authors aimed to estimate the incidence of cerebral sinus and venous thrombosis (CVT) within one month from first-dose administration and the frequency of vaccine-induced immune thrombotic thrombocytopenia (VITT) as the underlying mechanism after vaccination.

This retrospective and multicenter registry included patients with MS with suspected or confirmed COVID-19 diagnosis and available disease course (mild = ambulatory; severe = hospitalization; and critical = intensive care unit/death).

In this retrospective, multicenter cohort study, the authors compared patients with RRMS on EID (defined as ≥4-week delay of dose interval) with a control group on standard interval dosing (SID) at the same period (January to December 2020).

COVID-19 outcomes in patients with neurodegenerative disorders are not well understood, and the authors hypothesize there may be increased morbidity and mortality in this group. This retrospective cohort study was performed at three hospitals in the Chicagoland area.

In this article the authors compare SARS-CoV-2-specific CD4+ and CD8+ T cells against the B.1.1.7, B.1.351, P.1, and CAL.20C lineages in COVID-19 convalescents and in recipients of the Moderna (mRNA-1273) or Pfizer/BioNTech (BNT162b2) COVID-19 vaccines.

In this article the authors performed scRNA-seq on nasopharyngeal swabs from 58 healthy and COVID-19 participants.